Abstract:
To assess the clinical efficacy of mifepristone complicated with anemia and its effect on the hemoglobin, red
blood cell, as well as hematocrit. Sixty patients with hysteromyoma complicated with anemia between December 2018 and December 2020 were recruited and assigned to receive either mifepristone (control group, n=30) or mifepristone plus Shenqi Yangxue Granules (experimental group, n=30) based on the admission order. The two groups were compared in clinical efficiency, incidence of adverse reactions, myoma volume, uterine volume, and clinical indicators. The experimental group got a notably higher total treatment efficiency than the control group (P<0.05). The experimental group obtained a remarkably lower incidence of adverse reactions and smaller myoma volume and uterine volume than the control group (P<0.05). Patients in the experimental group showed lower hemoglobin levels and higher hematocrit levels than the control group (P<0.05). Combined therapy of mifepristone plus Shenqi Yangxue Granules resulted in lower erythrocyte aggregation index, erythrocyte sedimentation rate, in patients in the study group than those receiving
mifepristone alone in the control group (P<0.05). Mifepristone plus Shenqi Yangxue Granules for patients with
hysteromyoma complicated with anemia mitigates the clinical symptoms of patients and reduces the incidence of adverse reactions, with a high safety profile.
